Interference with this pathway by administration of CCR2 antagonist, CCL2 neutralizing antibody, or PI3 kinase inhibitor or by knockdown of CCL2 in prostate cancer PC3 cells all resulted in decreased tumor formation, smaller tumor size, and less metastases in vivo [82–84]. This evidence concerns the gene CCR2 and prostate cancer.